Furthermore, PD patients at the advanced stage demonstrated higher expression levels of APAF1 compared with the early stage (advanced stage: 0.43 ± 0.16, control: 0.32 ± 0.18, p = 0.011) (Table 2 and Figure 1A). This evidence concerns the gene APAF1 and Parkinson disease.